INmune Bio Announces Positive Results from CaRe PC Trial
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company, has achieved significant milestones in its Phase I/II CaRe PC trial. This trial focused on evaluating the efficacy of INKmune™, a novel treatment for metastatic castration-resistant prostate cancer (mCRPC). The company is excited to announce that the trial has met its primary and secondary endpoints, culminating in the closure of enrollments.
Positive Trial Outcomes and Safety Profile
The results from the CaRe PC trial indicate that INKmune™ has an impressive safety profile across all tested dose levels. This finding is notable as the primary endpoint of the trial was the safety of the treatment. Moreover, the study observed a correlation between low NK cell activation and significant improvements in biomarkers of NK cell activity, providing valuable insights for future trials.
Expert Insights on Treatment Efficacy
Dr. Mark Lowdell, Chief Scientific Officer at INmune Bio, expressed optimism about the trial results, stating that “INKmune was safe and effective at activating NK cells in a subset of more than half of these patients with advanced disease.” This statement underscores the potential of INKmune™ to not just activate NK cells but to potentially shrink tumor lesions, with some patients experiencing complete tumor regression during the treatment.
Future Directions for INKmune™
Following the encouraging outcomes of the CaRe PC trial, INmune Bio plans to embark on the next phase of clinical research. The roadmap includes formulating a randomized Phase 2b trial targeting patients with earlier stages of disease, aimed at facilitating a more comprehensive assessment of INKmune™'s clinical benefits. This strategic direction reflects the company's commitment to advancing treatments that leverage the body's natural immune responses against cancer.
Understanding INKmune™
INKmune™ is designed as a pharmaceutical-grade, replication-incompetent human tumor cell line. The formulation notably interacts with resting NK cells, delivering necessary signals that transform them into tumor-killing memory-like NK cells. This transformation enables patients' own NK cells to engage in combatting cancer cells effectively, displaying persistence beyond 100 days within the patient’s system.
Patient-Friendly Administration
This innovative treatment is designed with patient comfort in mind, as it does not require pre-medication or additional cytokine therapy. INKmune™ is administered via a simple intravenous infusion, making it accessible for outpatient treatment. It displays versatility, being tumor-agnostic; it has the potential to tackle various NK-resistant tumors, including cancers such as leukemia, lymphoma, and breast cancer.
About INmune Bio Inc.
INmune Bio Inc. (NASDAQ: INMB) is a publicly traded, clinical-stage biotechnology firm that aims to develop therapies to harness the innate immune system in combatting diseases. The company has three main product platforms. One notable platform is the Dominant-Negative Tumor Necrosis Factor (DN-TNF), which targets soluble TNF to mitigate innate immune dysfunction. This platform includes ongoing trials aimed at addressing conditions such as Mild Alzheimer’s disease and treatment-resistant depression. Another critical area is the Natural Killer Cell Priming Platform, which includes INKmune® and seeks to maximize the activity of patient NK cells against residual cancer. The third platform focuses on CORDStrom™, utilizing human umbilical cord-derived mesenchymal stem cells, which recently completed trials for a specific genetic condition. INmune Bio's approach leverages precision medicine, targeting chronic inflammation and cancer effectively.
Frequently Asked Questions
What are the key findings of the CaRe PC trial?
The CaRe PC trial successfully met its primary and secondary endpoints, showing a favorable safety profile for INKmune™.
How does INKmune™ work in treating mCRPC?
INKmune™ activates a patient's own NK cells, transforming them into memory-like NK cells that effectively combat cancer cells.
What is the next step for INmune Bio after this trial?
INmune Bio plans to initiate a randomized Phase 2b trial targeting patients with less severe disease to evaluate INKmune™'s effects further.
Is INKmune™ suitable for all cancer types?
Yes, INKmune™ is tumor-agnostic and can potentially treat various NK-resistant tumors.
Who can I contact for more information about INmune Bio?
For inquiries, you can contact David Moss at (858) 964-3720 or Daniel Carlson at (415) 509-4590.
